Aptamer-based therapeutics and their potential in radiopharmaceutical design

Ferreira, C. S. M.; Missailidis, Sotiris

doi:10.1590/s1516-89132007000600008

Cited by 28 publications

(17 citation statements)

References 79 publications

(92 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[553] The basic structural modifications to prevent nuclease degradation for improving pharmacokinetics have made reproducible synthesis of aptamers to be an expensive, lengthy process. [554] Additionally, the negative charge of aptamers due to their phosphodiester backbone is an obstacle to their deployment as targeting ligands by having direct effects on the blood circulation time and kinetics of the nanoparticles. [555] …”

Section: Aptamersmentioning

confidence: 99%

Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications

Mosayebi

Kiyasatfar

Laurent

2017

Adv Healthcare Materials

193

171

View full text Add to dashboard Cite

In order to translate nanotechnology into medical practice, magnetic nanoparticles (MNPs) have been presented as a class of non‐invasive nanomaterials for numerous biomedical applications. In particular, MNPs have opened a door for simultaneous diagnosis and brisk treatment of diseases in the form of theranostic agents. This review highlights the recent advances in preparation and utilization of MNPs from the synthesis and functionalization steps to the final design consideration in evading the body immune system for therapeutic and diagnostic applications with addressing the most recent examples of the literature in each section. This study provides a conceptual framework of a wide range of synthetic routes classified mainly as wet chemistry, state‐of‐the‐art microfluidic reactors, and biogenic routes, along with the most popular coating materials to stabilize resultant MNPs. Additionally, key aspects of prolonging the half‐life of MNPs via overcoming the sequential biological barriers are covered through unraveling the biophysical interactions at the bio–nano interface and giving a set of criteria to efficiently modulate MNPs' physicochemical properties. Furthermore, concepts of passive and active targeting for successful cell internalization, by respectively exploiting the unique properties of cancers and novel targeting ligands are described in detail. Finally, this study extensively covers the recent developments in magnetic drug targeting and hyperthermia as therapeutic applications of MNPs. In addition, multi‐modal imaging via fusion of magnetic resonance imaging, and also innovative magnetic particle imaging with other imaging techniques for early diagnosis of diseases are extensively provided.

show abstract

Section: Aptamersmentioning

confidence: 99%

Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications

Mosayebi

Kiyasatfar

Laurent

2017

Adv Healthcare Materials

193

171

View full text Add to dashboard Cite

show abstract

“…However, manufacturing costs are high as the technology has not yet evolved to generate large amounts within reasonable costs. 134…”

Section: Ease Of Synthesis and Manufacturingmentioning

confidence: 99%

Comparison of prostate‐specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer

et al. 2019

View full text Add to dashboard Cite

Background Prostate‐specific membrane antigen (PSMA), overexpressed on prostate cancer (PCa), is a well‐characterized cell surface protein to selectively diagnose PCa. PSMA's unique characteristics and its 1000‐fold higher expression in PCa compared with other tissues renders it as a suitable biomarker for detection of PCa in its early stage. In this report, we critically analyze and recommend the requirements needed for the development of variety of PSMA‐targeted molecular imaging agents based on antibodies, small molecule ligands, peptides, and aptamers. The targeting moieties are either conjugated to radionuclear isotopes or near‐infrared agents for efficient diagnosis of PCa. Recent findings From the analysis, it was found that several small molecule–derived PCa imaging agents are approved for clinical trials in Europe and the United States, and few are already in the clinical use for diagnosis of PCa. Even though 111In‐labeled capromab pendetide was approved by the Food and Drug Administration (FDA) and other engineered antibodies are available for detection of PCa, but high production cost, low shelf life (less than 1 month at 4°C), possibility of human immuno reactions, and low blood clearance rate necessitated a need for developing new imaging agents, which are serum stable, cost‐effective, and possesses longer shelf life (6 months), have fast clearance rate from nontargeted tissues during the diagnosis process. It is found that small molecule ligand‐derived imaging agents possesses most of the desired properties expected for an ideal diagnostic agent when compared with other targeting moieties. Conclusion This report discusses in detail the homing moieties used in the development of targeted diagnostic tools for detection of PCa. The merits and demerits of monoclonal antibodies, small molecule ligands, peptides, and aptamers for imaging of PCa and intraoperative guided surgery are extensively analyzed. Among all, urea‐based ligands were found to be most successful in preclinical and clinical trials and show a major promise for future commercialization.

show abstract

“…Aptamers as therapeutic or diagnostic agents in cancer have been recently reviewed (Khan and Missailidis, 2008;Makwana et al, 2008) as has the potential of aptamers as radiopharmaceuticals in the diagnostic imaging and targeted radiotherapy Missailidis and Perkins, 2007;Ferreira and Missailidis, 2007). Yet, references to aptamers in radiotherapy or as radiopharmaceuticals have been sporadic at best and the field is clearly lacking in development.…”

Section: Aptamers In the Literaturementioning

confidence: 99%

Aptamer-based radiopharmaceuticals for diagnostic imaging and targeted radiotherapy of epithelial tumors

Missailidis

Perkins

Santos-Filho

et al. 2008

Braz. arch. biol. technol.

Self Cite

View full text Add to dashboard Cite

show abstract

Aptamer-based therapeutics and their potential in radiopharmaceutical design

Cited by 28 publications

References 79 publications

Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications

Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications

Comparison of prostate‐specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer

Aptamer-based radiopharmaceuticals for diagnostic imaging and targeted radiotherapy of epithelial tumors

Contact Info

Product

Resources

About